Nerfasin vet. 100 mg/ml, solution for injection for cattle and horses

Authorised

- Xylazine hydrochloride

Product identification

Medicine name:
Nerfasin vet. 100 mg/ml, solution for injection for cattle and horses

Active substance:
Xylazine hydrochloride

Target species:
Cattle
Horse

Route of administration:
Intramuscular use
Intravenous use

Product details

Active substance and strength:
Xylazine hydrochloride
116.55 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Solution for injection

Withdrawal period by route of administration:

Intramuscular use:

- **Cattle**
  - Milk. 0 day
  - Meat and offal. 1 day
- **Horse**
  - Milk. 0 day
  - Meat and offal. 1 day

Intravenous use:

- **Cattle**
  - Milk. 0 day
  - Meat and offal. 1 day
- **Horse**
  - Milk. 0 day
  - Meat and offal. 1 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QN05CM92

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

France

Available in:
France

Package description:
10 ml product in a 10 ml clear type II glass vials closed with a bromobutyl rubber stopper and aluminium cap in a carton box.
25 ml product in a 30 ml clear type II glass vials closed with a bromobutyl rubber stopper and aluminium cap in a carton box.
50 ml product in a 50 ml clear type II glass vials closed with a bromobutyl rubber stopper and aluminium cap in a carton box.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Le Vet. B.V.

Marketing authorisation date:
3/05/2012

Manufacturing sites for batch release:
Produlab Pharma B.V.

Responsible authority:
French Agency For Food, Environmental And Occupational Health & Safety

Authorisation number:
FR/V/0357396 9/2012

Date of authorisation status change:
19/06/2017

Reference member state:
Netherlands

Procedure number:
NL/V/0157/002

Concerned member states:
Austria Belgium Czechia Denmark Finland France Greece Hungary Iceland Ireland Italy Luxembourg Norway Poland Portugal Slovakia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents

108959 - par.pdf